Skip to main content

Table 3 DLQI Scores by clinical factors in patients with psoriasis

From: The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study

Variables No. of patients DLQI Scores p-value DLQI ≤10 DLQI ≥11 p-value
Mean ± SD N (%) N (%)
Total participants 299 12.4 ± 7.6   138 (46.2) 161 (53.8)  
Duration of psoriasis (years)
 1–9 33 14.8 ± 8.3 0.201 14 (42.4) 19 (57.6) 0.661
 10–19 113 12.6 ± 7.8   50 (44.2) 63 (55.8)  
 20–29 89 11.5 ± 7.6   46 (51.7) 43 (48.3)  
  ≥ 30 64 12.0 ± 6.9   28 (43.8) 36 (56.3)  
Severity of psoriasis (BSA)
 Mild (< 5%) 146 10.5 ± 6.9 < 0.001 80 (54.8) 66 (45.2) 0.005
 Moderate (5–9%) 65 13.0 ± 7.6   29 (44.6) 36 (55.4)  
 Severe (≥10%) 88 15.0 ± 8.0   29 (33.0) 59 (67.0)  
Site of psoriasis
 Head 233 13.0 ± 7.8 0.010 101 (43.3) 132 (56.7) 0.067
 Face 141 14.4 ± 8.2 < 0.001 54 (38.3) 87 (61.7) 0.010
 Neck 82 16.0 ± 7.5 < 0.001 21 (25.6) 61 (74.4) < 0.001
 Shoulder 115 15.2 ± 7.8 < 0.001 41 (35.7) 74 (64.3) 0.004
 Chest/abdomen 191 13.5 ± 7.6 0.001 74 (38.7) 117 (61.3) 0.001
 Back/buttocks 232 13.5 ± 7.7 < 0.001 93 (40.1) 139 (59.9) < 0.001
 Arm 229 13.2 ± 7.8 0.001 97 (42.4) 132 (57.6) 0.017
 Hand 141 14.2 ± 7.7 < 0.001 51 (36.2) 90 (63.8) 0.001
 Leg 263 12.4 ± 7.7 0.916 120 (45.6) 143 (54.4) 0.622
 Foot 128 14.7 ± 7.6 < 0.001 43 (33.6) 85 (66.4) < 0.001
Treatment for psoriasis
 Topical treatment 246 12.8 ± 7.6 0.048 107 (43.5) 139 (56.5) 0.047
 Prescribed oral medication 135 14.8 ± 7.9 < 0.001 44 (32.6) 91 (67.4) < 0.001
 Herbal medication 88 14.2 ± 7.8 0.009 30 (34.1) 58 (65.9) 0.007
 Phototherapy 142 13.8 ± 8.1 0.002 57 (40.1) 85 (59.9) 0.047
 Injections except biologics 45 15.1 ± 8.6 0.011 16 (35.6) 29 (64.4) 0.122
 Biological therapy 28 11.8 ± 8.9 0.636 14 (50.0) 14 (50.0) 0.668
  1. DLQI Dermatology life quality index; BSA: body surface area